Biomolecular Interaction Analysis Services

Knowing that two molecules interact is only the start. What matters for research and development is how strongly they bind, how that binding behaves over time, and — for antibodies — how much antibody is present and where it recognizes its target. We provide an integrated set of biomolecular interaction analysis services: general binding characterization for protein, small-molecule, and nucleic-acid partners, and dedicated antibody–antigen characterization for antibody and peptide work. Together, these services turn observations into quantitative, comparable data that can support target validation, hit ranking, and antibody selection.

A single interaction can be described from several angles, and the right angle depends on the question. Affinity and kinetics explain strength and duration; stability tells you whether a complex will survive its conditions; titer and isotype place an antibody in context; epitope mapping explains its behavior. By covering the non-antibody and antibody cases with one partner, customers keep their measurements consistent across a project rather than re-interpreting results produced under different conditions by different providers.

Why Interaction Analysis Matters

A binding result is only useful when it is quantitative, reproducible, and tied to a decision:

• Decision-ready data – replacing "it binds" with affinity and kinetic values that let candidates be ranked and compared.
• Comparability – measuring a series under one protocol so the numbers mean the same thing across every partner or variant.
• Mechanistic insight – distinguishing competitive from non-competitive binding, or activation from inhibition, through how binding changes.
• Risk reduction – confirming that a candidate or clone behaves as expected before it is carried into the next stage.

A Combined View of Interaction Analysis

Interaction measurements fall into two analyte groups. Each answers a different kind of question, and both are supported within a single workflow:

• Non-antibody partners – protein–protein, protein–small molecule, and protein–nucleic acid interactions, characterized by how tightly and how fast they bind and whether the complex stays stable.
• Antibody partners – antibody–antigen and antibody–peptide interactions, characterized by how much antibody is present, what class it is, and which part of the target it recognizes.

Using one consistent approach across both groups keeps the logic of the project coherent, from a first binding measurement to a final selection or pairing decision.

Service Areas

Which Service Fits Your Need

How We Support Your Program

• Method consultation – advice on which readouts fit the partners and the question, and on sample preparation.
• Multiple readouts under one roof – affinity, kinetics, stability, titer, isotype, and epitope analysis run within a single workflow.
• Documented outputs – constants, curves, and comparative summaries that can enter your project record directly.
• Flexible engagement – from a single interaction measurement to ongoing characterization across a panel or a program.

An Integrated Approach

Because the non-antibody and antibody cases share the same measurement discipline, customers can move smoothly from a first binding measurement to a final selection or pairing decision without changing suppliers. This continuity reduces re-interpretation, keeps every result comparable, and maintains the same data quality from characterization through selection — turning interaction analysis from a set of separate measurements into a managed, end-to-end picture of how molecules recognize one another.